SWOG-S1406

NCT02164916 📎

Regimen

Experimental
Vemurafenib (BRAF inhibitor) + irinotecan + cetuximab
Control
Irinotecan + cetuximab

Population

BRAF V600E-mutant, RAS wild-type metastatic CRC, 2L (1–2 prior regimens).

Key finding

Irinotecan + cetuximab + vemurafenib vs irinotecan + cetuximab: PFS HR 0.50 (improved; P value significant per paper); ORR improvement with vemurafenib addition; the triplet demonstrated proof-of-concept for simultaneous BRAF+EGFR+iri targeting, forming the rationale for BEACON CRC.

Source: PMID 33356422

Timeline

    Guideline citations

    • NCCN Colon (p.149)